Table 2.
Maximum grade adverse event per patient (Grade 2–4 only as per CTCAE V.4.0) attributed as possibly, probably, or definitely related to talimogene laherparepvec
| Toxicity | Grade | ||
| 2 | 3 | 4 | |
| Anemia | 3 | 2 | 0 |
| Diarrhea | 2 | 0 | 0 |
| Nausea | 6 | 0 | 0 |
| Vomiting | 4 | 2 | 0 |
| Chills | 18 | 1 | 0 |
| Leg edema | 1 | 0 | 0 |
| Fatigue | 19 | 3 | 0 |
| Fever | 4 | 0 | 0 |
| Influenza like symptoms | 6 | 1 | 0 |
| Injection site reaction | 5 | 0 | 0 |
| Malaise | 2 | 0 | 0 |
| Pain | 5 | 1 | 0 |
| Skin infection | 1 | 0 | 0 |
| Lymphopenia | 6 | 2 | 2 |
| Weight loss | 3 | 1 | 0 |
| Anorexia | 1 | 1 | 0 |
| Back pain | 1 | 0 | 0 |
| Generalized muscle weakness | 2 | 1 | 0 |
| Pain in extremity | 3 | 3 | 0 |
| Dizziness | 1 | 0 | 0 |
| Dysgeusia | 1 | 0 | 0 |
| Headache | 2 | 1 | 0 |
| Neuralgia | 1 | 0 | 0 |
| Depression | 2 | 0 | 0 |
| Proteinuria | 0 | 1 | 0 |
| Renal and urinary disorders | 1 | 0 | 0 |
| Hiccups | 1 | 0 | 0 |
| Hypertension | 1 | 1 | 0 |
| Hypotension | 1 | 0 | 0 |
| Total | 65 | 17 | 2 |
CTCAE, Common Terminology Criteria for Adverse Events.